AtriCure 2026 Stifel Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good afternoon, everyone. Hope everybody had a nice lunch. For those listening, my name is John McAulay. I am one of the medical technology analysts here at Stifel. It is my pleasure to welcome AtriCure to the 2026 Stifel Healthcare Conference. Today, we have the company's President and CEO, Mike Carrel, along with the Chief Financial Officer, Angie Wirick. Thank you both for being here.
Thanks for having us. Thanks, John.
I am going to start off today on the third quarter results, the updated 2026 guidance you provided before getting into some more product-specific clinical data-oriented questions. First, just to start off with the 2026 guidance you gave, updated now to $606 million-$610 million for the fourth quarter implies something like 11%-14% growth. But in the third quarter, you just grew 15%, growth accelerated. It seems like you have a lot of tailwinds, pain management, open heart. Just wanted to talk through the 4Q dynamics and whether the implied slowdown at the midpoint reflects any specific dynamics in the quarter or just your typical prudent guidance approach.
It's going to be the latter, so typical prudent conservatism. When we guide to numbers, we want to make sure that we can not only just deliver the numbers, but there's a pathway to a beat. I think we feel confidence in the same tailwinds that you've called out. There were several areas of the business where we saw an acceleration in our U.S. company, which was exciting, and we still think that we've got that good kind of momentum. I'd say two areas that we thought through in terms of headwinds for us, our international business, and then also our U.S. hybrid business, and being mindful of kind of that full compilation in the results as we thought about the fourth quarter.
That's helpful. I'm going to ask about next year, as you might expect, but I'm going to do it through the framework you gave at the 2025 Analyst Day.
Sure. You gave longer-term targets for 2028, $750 million in revenues, 14% adjusted EBITDA margin.
Seems like you're tracking ahead of that at this point. There's been some incremental dynamics. BoxX has enrolled faster than expected. There's this STS quality metric which is going into effect, which I don't think we were aware of when that plan was provided. So, I just wanted to get a sense, that growth rate sort of implied 12%-13% in these years leading up to 2028. Is there a chance for you that 2027, given these tailwinds, can perhaps be a better year than you would have contemplated back in 2025?
I think that's a fair assessment. When we gave the initial LRP, the key messages that investors should take away from that is confidence in continued double-digit revenue growth, so in the kind of the mid-teens range there. We've obviously outperformed that the last two years, and there are a couple of new catalysts, either completely new, like the quality metrics that you talked about, or BoxX-NoAF. When we gave that LRP, we expected trial enrollment and data that's coming at a later date than what we are going to see today. So, I think that there are a lot of things that are tailwinds for our business that would say continued outperformance to the LRP.
Thanks. That's helpful. Thinking about gross margins as well, just as I look at where next year is, I think consensus is actually a little below where you are this year, but it seems like the business is being driven by some particularly high-margin drivers. That's where growth is centered, seems to be pain management, EnCompass, AtriClip. Could it be possible that 2027 gross margins are below 2026? Just walk me through maybe how you're thinking about these dynamics next year.
Yeah. The biggest headwind we face relative to gross margin is the expansion of our manufacturing facility. So added on, effectively doubling our production capability by adding on to current corporate headquarters, right there in kind of a campus setting. Again, we're doing this when you think long term. We have a strong belief in our outlook here and wanted to make sure that we could support the volumes that we expect to generate longer term. I think that's the biggest headwind when we think about a full year of that facility cost, very new, won't quite fully maximize capacity in the near term. I think what you're seeing out of the business today is with newer product launches and them becoming a bigger component of our overall revenue, that we've got the quality of devices that can yield a very high gross margin.
That gives us an outlook longer term that's very positive.
I see. I also wanted to go back to your Analyst Day again, because you did give a sort of long-term adjusted EBITDA.
Yes margin range. I think this year, the midpoint implies about a 15% margin.
Your margin target for 2028 was just 14%, so you are running well ahead of schedule. I wanted to ask then, do you see this as an opportunity to reinvest in the business, or do you see this as an opportunity to let some of this cash flow back into the business and maybe use for external investments?
I think you have hit on the two areas that we are focused on. When we talked about our guidance specifically for the fourth quarter, when we thought about overall profitability, given the progress that we have made these past two years and where we are tracking, we had the confidence to say, lean in in a couple of areas, specifically when you think about new product development. Spend more, invest more in research, and start kicking off projects a bit quicker. So, we are reinvesting in the business. All that being said, continue to make progress on bottom line. I think it is a pretty enviable position that we are in, that we are able to be able to do both and feel good about the progress overall of the business.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
3 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
